You searched for Investor Event

PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. ...

- 07 July 2026

Ipsen – Half year statement – 2026 06 30

Half-year statement of the liquidity agreement between IPSEN SA and NATIXIS ODDO BHF...

- 03 April 2026

Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

PARIS, FRANCE, 3 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) announces that Beech Tree — which directly and indirectly holds 26.03% of Ipsen S.A.’s share capital and 33.05% of its voting rights — has obtained from the French Financial Markets A...

- 13 May 2026

Ipsen S.A. – Evolution of the composition of the Board of Directors

Ipsen S.A. – Evolution of the composition of the Board of Directors...

- 29 May 2026

Ipsen announces the launch of an Employee Shareholding Plan

Ipsen announces the launch of an employee shareholding plan...

Search results

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Ipsen nominates Catherine Bradley to its Board of Directors as independent Director

Ipsen S.A. – Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026

Ipsen initiates a new share buy-back program

Ipsen announces the availability of its 2025 Universal Registration Document

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

Ipsen – Half year statement – 2026 06 30

Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

Ipsen S.A. – Evolution of the composition of the Board of Directors

Ipsen announces the launch of an Employee Shareholding Plan

We value your feedback